Dupilumab
Treatment for Eczema
Typical Dosage: 600 mg initial, then 300 mg SC every two weeks
Effectiveness
90%
Safety Score
60%
Clinical Trials
108
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
600 mg initial, then 300 mg SC every two weeks
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$39,000
Monitoring:$400
Side Effect Mgmt:$100
Total Annual:$39,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$135,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$60,769
Cost per Remission
$158,000
Comparison vs Cyclosporine + Topical Corticosteroids
Cost Difference
+$34,500/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Dupilumab Outcomes
for Eczema
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+65%
Remission Rate
+25%
Common Side Effects
Injection site reactions
+15%
Conjunctivitis
+10%
Oral herpes
+3%
Eosinophilia
+3%
Sources:
Active Clinical Trials
10 active trials recruiting for Dupilumab in Eczema
DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
NCT06004986RECRUITINGPHASE4
216 participants
INTERVENTIONAL
Amsterdam, Netherlands +1 more
Started: Aug 14, 2023
Dupixent and Narrowband UVB for Atopic Dermatitis
NCT05285839RECRUITINGPHASE4
40 participants
INTERVENTIONAL
East Windsor, United States
Started: Apr 19, 2022
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
NCT06169527ACTIVE NOT RECRUITING
303 participants
OBSERVATIONAL
Amiens, France +41 more
Started: Nov 28, 2023
Ethnic Differences in Mechanisms of Action of Dupilumab
NCT05268107RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Ann Arbor, United States
Started: Jan 25, 2023
Dupilumab De-escalation in Pediatric Atopic Dermatitis
NCT06116526RECRUITINGPHASE4
30 participants
INTERVENTIONAL
Baltimore, United States
Started: Apr 1, 2024
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
NCT05042258RECRUITINGPHASE4
40 participants
INTERVENTIONAL
Chicago, United States
Started: Aug 12, 2024
Molecular Signatures of Cutaneous Dupilumab Response
NCT05858619RECRUITINGPHASE4
15 participants
INTERVENTIONAL
San Francisco, United States
Started: Feb 1, 2023
Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain
NCT06415175RECRUITING
150 participants
OBSERVATIONAL
Santiago de Compostela, Spain +14 more
Started: Nov 14, 2024
Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema
NCT04600362ACTIVE NOT RECRUITINGPHASE2
70 participants
INTERVENTIONAL
München, Germany
Started: Mar 30, 2021
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®
NCT06884891NOT YET RECRUITINGPHASE3
520 participants
INTERVENTIONAL
Started: Apr 1, 2025
Completed Clinical Trials
7 completed trials for Dupilumab in Eczema
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
NCT03293030COMPLETEDPHASE4
17 participants
INTERVENTIONAL
San Francisco, United States
Started: Oct 22, 2018
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
NCT03667014COMPLETEDPHASE4
34 participants
INTERVENTIONAL
San Francisco, United States
Started: Nov 1, 2018
Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
NCT03861455COMPLETEDPHASE2
94 participants
INTERVENTIONAL
Bordeaux, France +3 more
Started: Jul 15, 2019
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
NCT01949311COMPLETEDPHASE3
2.73K participants
INTERVENTIONAL
Anniston, United States +431 more
Started: Oct 10, 2013
Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China
NCT05680298COMPLETEDPHASE4
34 participants
INTERVENTIONAL
Beijing, China
Started: Feb 22, 2023
A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)
NCT02407756COMPLETEDPHASE2
78 participants
INTERVENTIONAL
Markham, Canada +25 more
Started: Mar 31, 2015
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
NCT04358224COMPLETEDPHASE4
12 participants
INTERVENTIONAL
Cincinnati, United States
Started: Sep 1, 2020
Showing 20 of 109 total trials